Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of D5884 (Epanova) in Healthy Japanese and Caucasian Males
NCT02209766Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia (3 cohorts), sponsored by AstraZeneca. Primary endpoint: Treatment-emergent Adverse Events. Started Aug 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT02209766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209766.